AngioDynamics (NASDAQ:ANGO) issued its quarterly earnings results on Tuesday, April 2nd. The medical instruments supplier reported $0.19 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.03), MarketWatch Earnings reports. AngioDynamics had a net margin of 1.30% and a return on equity of 5.41%. The business had revenue of $86.34 million during the quarter, compared to analyst estimates of $88.30 million. During the same period in the previous year, the company posted $0.23 earnings per share. AngioDynamics’s revenue was up 3.0% compared to the same quarter last year. AngioDynamics updated its FY 2019 guidance to $0.82-0.86 EPS and its FY19 guidance to $0.82-0.86 EPS.
ANGO stock traded up $0.14 during midday trading on Wednesday, hitting $20.64. 157,900 shares of the company traded hands, compared to its average volume of 237,238. AngioDynamics has a twelve month low of $18.11 and a twelve month high of $25.48. The company has a quick ratio of 1.70, a current ratio of 2.68 and a debt-to-equity ratio of 0.23. The company has a market cap of $762.93 million, a PE ratio of 27.89 and a beta of 0.75.
A number of analysts have recently issued reports on ANGO shares. BidaskClub lowered shares of AngioDynamics from a “hold” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Thursday, April 11th. Canaccord Genuity increased their price target on shares of AngioDynamics from $20.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, January 7th. TheStreet downgraded AngioDynamics from a “b” rating to a “c+” rating in a report on Thursday, April 18th. Finally, ValuEngine downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, April 19th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. The company has an average rating of “Hold” and an average target price of $23.50.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.